Ensysce Biosciences amends Series C preferred terms, removes holder cash redemption right

Bitget2026/09/29 12:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ensysce Biosciences amended the certificate of designation for its Series C Non-Voting Convertible Preferred Stock on Sept. 25, 2026 to eliminate a holder cash-redemption right tied to failed share delivery.
The removed provision had allowed holders to demand cash redemption at any time following shareholder approval for conversion into common stock under Nasdaq rules.
Redemption pricing was set at the then-current fair value of the Series C preferred shares.
The amendment took effect upon filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-044802), on September 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ensysce Biosciences amends Series C preferred terms, removes holder cash redemption right

You may also like

Crypto prices